In Brief This Week: Illumina; FDA, Exact Sciences, Epigenomics; Source BioScience; Bureau Veritas, Maxxam Analytics International; 1st Detect, Rigaku | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina said this week that its board has authorized the repurchase of up to $250 million of the company's common stock. The new repurchase program is in addition to Illumina's current program, which has $117.5 million available for share repurchases.


The US Food and Drug Administration confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review Exact Sciences' premarket approval application for the Cologuard colorectal screening test on March 27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?